Surveillance for Adverse Events After COVID-19 mRNA Vaccinat
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Importance Safety surveillance of vaccines against COVID-19 is critical to ensure safety, maintain trust, and inform policy.


To monitor 23 serious outcomes weekly, using comprehensive health records on a diverse population.

Design, Setting, and Participants:

This study represents an interim analysis of safety surveillance data from Vaccine Safety Datalink. The 10?162?227 vaccine-eligible members of 8 participating US health plans were monitored with administrative data updated weekly and supplemented with medical record review for selected outcomes from December 14, 2020, through June 26, 2021.


Receipt of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) COVID-19 vaccination, with a risk interval of 21 days for individuals after vaccine dose 1 or 2 compared with an interval of 22 to 42 days for similar individuals after vaccine dose 1 or 2.

Main Outcomes and Measures:

Incidence of serious outcomes, including acute myocardial infarction, Bell palsy, cerebral venous sinus thrombosis, Guillain-Barré syndrome, myocarditis/pericarditis, pulmonary embolism, stroke, and thrombosis with thrombocytopenia syndrome.

Incidence of events that occurred among vaccine recipients 1 to 21 days after either dose 1 or 2 of a messenger RNA (mRNA) vaccine was compared with that of vaccinated concurrent comparators who, on the same calendar day, had received their most recent dose 22 to 42 days earlier.

Rate ratios (RRs) were estimated by Poisson regression, adjusted for age, sex, race and ethnicity, health plan, and calendar day. For a signal, a 1-sided P?less than?.0048 was required to keep type I error below .05 during 2 years of weekly analyses. For 4 additional outcomes, including anaphylaxis, only descriptive analyses were conducted.


A total of 11?845?128 doses of mRNA vaccines were administered to 6.2 million individuals. The incidence of events per 1?000?000 person-years during the risk vs comparison intervals for ischemic stroke was 1612 vs 1781; for appendicitis, 1179 vs 1345; and for acute myocardial infarction, 935 vs 1030. No vaccine-outcome association met the prespecified requirement for a signal. Incidence of confirmed anaphylaxis was 4.8 per million doses of BNT162b2 and 5.1 per million doses of mRNA-1273.

Conclusions and Relevance:

In interim analyses of surveillance of mRNA COVID-19 vaccines, the incidence of selected serious outcomes was not significantly higher 1 to 21 days postvaccination compared with 22 to 42 days postvaccination. While CIs were wide for many outcomes, surveillance is ongoing.